Initiation of DNA interstrand cross‐link repair in mammalian cells

Citations Over TimeTop 10% of 2010 papers

Abstract

Interstrand cross-links (ICLs) are among the most cytotoxic DNA lesions to cells because they prevent the two DNA strands from separating, thereby precluding replication and transcription. Even though chemotherapeutic cross-linking agents are well established in clinical use, and numerous repair proteins have been implicated in the initial events of mammalian ICL repair, the precise mechanistic details of these events remain to be elucidated. This review will summarize our current understanding of how ICL repair is initiated with an emphasis on the context (replicating, transcribed or quiescent DNA) in which the ICL is recognized, and how the chemical and physical properties of ICLs influence repair. Although most studies have focused on replication-dependent repair because of the relation to highly replicative tumor cells, replication-independent ICL repair is likely to be important in the circumvention of cross-link cytotoxicity in nondividing, terminally differentiated cells that may be challenged with exogenous or endogenous sources of ICLs. Consequently, the ICL repair pathway that should be considered "dominant" appears to depend on the cell type and the DNA context in which the ICL is encountered. The ability to define and inhibit distinct pathways of ICL repair in different cell cycle phases may help in developing methods that increase cytotoxicity to cancer cells while reducing side-effects in nondividing normal cells. This may also lead to a better understanding of pathways that protect against malignancy and aging.

Related Papers

• → Functional interplay between ATM/ATR-mediated DNA damage response and DNA repair pathways in oxidative stress(2014)238 cited
• → Interplay between DNA repair and inflammation, and the link to cancer(2014)176 cited
• → DNA damage repair and cardiovascular diseases(2010)42 cited
• → Cellular Responses to DNA Damage(2017)2 cited
• → The role of progesterone-induced blocking factor (PIBF) in invasion of primary ovarian tumour cells(2017)